How did Veracyte's revenue and expenses trend in Q4 2024?

Veracyte's revenue and expenses in Q4 2024 showed a notable increase in R&D and selling, general, and administrative expenses, with intangible asset amortization also contributing to the expense side, while revenue remained at $0. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |VCYT|VCYT.O|Veracyte|20240101-2024|Intangible Asset Amortization|0|185| |VCYT|VCYT.O|Veracyte|20240101-2024|Biopharmaceutical|9692000|185| |VCYT|VCYT.O|Veracyte|20240101-2024|Biopharmaceutical|6556000|185| |VCYT|VCYT.O|Veracyte|20240101-2024|Biopharmaceutical|3004000|185| |VCYT|VCYT.O|Veracyte|20240101-2024|Product|3537000|185| |VCYT|VCYT.O|Veracyte|20240101-2024|Testing|9.0303E7|185| |VCYT|VCYT.O|Veracyte|20240101-2024|Biopharmaceutical|3004000|185| |code|Ticker|Name|Date|Selling, General, and Administrative Expenses|R&D Expenses|market_code| |---|---|---|---|---|---|---| |VCYT|VCYT.O|Veracyte|2024 Q1|5.3645E7|1.5965E7|185| |VCYT|VCYT.O|Veracyte|2024 Q2|5.6842E7|1.6465E7|185| |VCYT|VCYT.O|Veracyte|2024 Q3|5.2151E7|1.7574E7|185| |VCYT|VCYT.O|Veracyte|2024 Q4|5.5346E7|1.929E7|185|